David R Martinez
Overview
Explore the profile of David R Martinez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
10623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Diefenbacher M, Baric T, Martinez D, Baric R, Catanzaro N, Sheahan T
Virus Res
. 2023 Nov;
339:199286.
PMID: 38016504
The genetic diversity of the coronavirus (CoV) family poses a significant challenge for drug discovery and development. Traditional antiviral drugs often target specific viral proteins from specific viruses which limits...
12.
Schafer A, Martinez D
Sci Immunol
. 2023 Nov;
8(89):eadl5685.
PMID: 37931035
Non-antigen vaccines that broadly activate innate immune responses reduce mortality against hospital-acquired bacterial and fungal pathogens.
13.
Martinez D, Schafer A, Gavitt T, Mallory M, Lee E, Catanzaro N, et al.
Cell Rep
. 2023 Oct;
42(10):113248.
PMID: 37858337
The emergence of three highly pathogenic human coronaviruses-severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003, Middle Eastern respiratory syndrome (MERS)-CoV in 2012, and SARS-CoV-2 in 2019-underlines the need to develop...
14.
Tse L, Hou Y, McFadden E, Lee R, Scobey T, Leist S, et al.
Sci Transl Med
. 2023 Sep;
15(715):eadg5567.
PMID: 37756379
The repeated emergence of zoonotic human betacoronaviruses (β-CoVs) dictates the need for broad therapeutics and conserved epitope targets for countermeasure design. Middle East respiratory syndrome (MERS)-related coronaviruses (CoVs) remain a...
15.
Hou Y, Chiba S, Leist S, Meganck R, Martinez D, Schafer A, et al.
Nat Microbiol
. 2023 Sep;
8(10):1820-1833.
PMID: 37749254
The pathogenic and cross-species transmission potential of SARS-CoV-2-related coronaviruses (CoVs) remain poorly characterized. Here we recovered a wild-type pangolin (Pg) CoV GD strain including derivatives encoding reporter genes using reverse...
16.
Guseman A, Rennick L, Nambulli S, Roy C, Martinez D, Yang D, et al.
Proc Natl Acad Sci U S A
. 2023 Sep;
120(38):e2301518120.
PMID: 37695910
SARS-CoV-2 spike harbors glycans which function as ligands for lectins. Therefore, it should be possible to exploit lectins to target SARS-CoV-2 and inhibit cellular entry by binding glycans on the...
17.
Martinez D, Moreira F, Zweigart M, Gully K, De la Cruz G, Brown A, et al.
bioRxiv
. 2023 Jul;
PMID: 37425890
Despite the wide availability of several safe and effective vaccines that can prevent severe COVID-19 disease, the emergence of SARS-CoV-2 variants of concern (VOC) that can partially evade vaccine immunity...
18.
Martinez D, Schafer A, Gavitt T, Mallory M, Lee E, Catanzaro N, et al.
bioRxiv
. 2023 Jun;
PMID: 37293083
The emergence of three distinct highly pathogenic human coronaviruses - SARS-CoV in 2003, MERS-CoV in 2012, and SARS-CoV-2 in 2019 - underlines the need to develop broadly active vaccines against...
19.
Langel S, Martinez D
Sci Immunol
. 2023 Jun;
8(84):eadi8769.
PMID: 37276436
Endogenous retrovirus antibody responses contribute to survival after immune checkpoint blockade therapy against lung adenocarcinoma.
20.
Zhou P, Song G, Liu H, Yuan M, He W, Beutler N, et al.
Immunity
. 2023 Mar;
56(3):669-686.e7.
PMID: 36889306
Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against novel pandemic coronaviruses and to more effectively respond to SARS-CoV-2 variants. The emergence of Omicron and subvariants...